JP2023548346A - アクチビン／ｔｇｆ－ベータおよびｒａｎｋｌの二機能性アンタゴニストならびにその使用 - Google Patents

アクチビン／ｔｇｆ－ベータおよびｒａｎｋｌの二機能性アンタゴニストならびにその使用 Download PDF

Info

Publication number
JP2023548346A
JP2023548346A JP2023526553A JP2023526553A JP2023548346A JP 2023548346 A JP2023548346 A JP 2023548346A JP 2023526553 A JP2023526553 A JP 2023526553A JP 2023526553 A JP2023526553 A JP 2023526553A JP 2023548346 A JP2023548346 A JP 2023548346A
Authority
JP
Japan
Prior art keywords
amino acid
seq
antibody
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548346A5 (https=
Inventor
ハン，ハック
シュウ，シャオラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2023548346A publication Critical patent/JP2023548346A/ja
Publication of JP2023548346A5 publication Critical patent/JP2023548346A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023526553A 2020-11-11 2021-11-05 アクチビン／ｔｇｆ－ベータおよびｒａｎｋｌの二機能性アンタゴニストならびにその使用 Pending JP2023548346A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063112380P 2020-11-11 2020-11-11
US63/112,380 2020-11-11
US202063113922P 2020-11-15 2020-11-15
US63/113,922 2020-11-15
PCT/US2021/058181 WO2022103660A1 (en) 2020-11-11 2021-11-05 Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof

Publications (2)

Publication Number Publication Date
JP2023548346A true JP2023548346A (ja) 2023-11-16
JP2023548346A5 JP2023548346A5 (https=) 2024-11-08

Family

ID=81601668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526553A Pending JP2023548346A (ja) 2020-11-11 2021-11-05 アクチビン／ｔｇｆ－ベータおよびｒａｎｋｌの二機能性アンタゴニストならびにその使用

Country Status (7)

Country Link
EP (1) EP4243931A4 (https=)
JP (1) JP2023548346A (https=)
KR (1) KR20230118573A (https=)
AU (1) AU2021377176A1 (https=)
CA (1) CA3197104A1 (https=)
MX (1) MX2023005565A (https=)
WO (1) WO2022103660A1 (https=)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535032A (ja) * 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
JP2011225581A (ja) * 1999-09-03 2011-11-10 Amgen 癌および癌に関連する骨損失の予防または治療のための組成物および方法
JP2013504589A (ja) * 2009-09-09 2013-02-07 アクセルロン ファーマ， インコーポレイテッド ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP5174466B2 (ja) * 2005-02-08 2013-04-03 ジェンザイム・コーポレーション ＴＧＦβに対する抗体
JP2013521311A (ja) * 2010-03-05 2013-06-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
JP5497438B2 (ja) * 2006-09-08 2014-05-21 アムジエン・インコーポレーテツド 抗アクチビンａ抗体およびその使用
JP2015514082A (ja) * 2012-03-31 2015-05-18 アール−ファーム・クローズド・ジョイント・ストック・カンパニーＲ−Ｐｈａｒｍ， ＣＪＳＣ オステオプロテゲリン由来の組成物およびその使用
JP2015180627A (ja) * 2009-03-19 2015-10-15 中外製薬株式会社 抗体定常領域改変体
JP2015536349A (ja) * 2012-11-21 2015-12-21 アムジエン・インコーポレーテツド ヘテロ二量体免疫グロブリン
JP2016514463A (ja) * 2013-03-15 2016-05-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
JP2016528232A (ja) * 2013-07-30 2016-09-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗アクチビンａ抗体及びその使用
JP2018510637A (ja) * 2015-03-26 2018-04-19 アクセルロン ファーマ， インコーポレイテッド フォリスタチン関連融合タンパク質およびその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526792A (ja) * 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質
EP2401296A1 (en) * 2009-02-24 2012-01-04 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
CN105431453A (zh) * 2012-11-01 2016-03-23 艾伯维公司 稳定的双重可变结构域免疫球蛋白制剂
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
US10227411B2 (en) * 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
WO2018009732A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2018026742A1 (en) * 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
SI4190355T1 (sl) * 2017-04-28 2025-02-28 Amgen Inc. Formulacije humanih protiteles proti-RANKL in postopki njihove uporabe
WO2019079762A1 (en) * 2017-10-20 2019-04-25 Children's National Medical Center METHODS OF DISCOVERING ANTIBODIES USING TRANSCRIPTOMES AND COMPOSITIONS DERIVED THEREFROM
AU2019394364A1 (en) * 2018-12-05 2021-06-17 The Council Of The Queensland Institute Of Medical Research Rank antagonists and uses therefor

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011225581A (ja) * 1999-09-03 2011-11-10 Amgen 癌および癌に関連する骨損失の予防または治療のための組成物および方法
JP5174466B2 (ja) * 2005-02-08 2013-04-03 ジェンザイム・コーポレーション ＴＧＦβに対する抗体
JP5497438B2 (ja) * 2006-09-08 2014-05-21 アムジエン・インコーポレーテツド 抗アクチビンａ抗体およびその使用
JP2010535032A (ja) * 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
JP2015180627A (ja) * 2009-03-19 2015-10-15 中外製薬株式会社 抗体定常領域改変体
JP2013504589A (ja) * 2009-09-09 2013-02-07 アクセルロン ファーマ， インコーポレイテッド ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用
JP2013521311A (ja) * 2010-03-05 2013-06-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
JP2015514082A (ja) * 2012-03-31 2015-05-18 アール−ファーム・クローズド・ジョイント・ストック・カンパニーＲ−Ｐｈａｒｍ， ＣＪＳＣ オステオプロテゲリン由来の組成物およびその使用
JP2015536349A (ja) * 2012-11-21 2015-12-21 アムジエン・インコーポレーテツド ヘテロ二量体免疫グロブリン
JP2016514463A (ja) * 2013-03-15 2016-05-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
JP2016528232A (ja) * 2013-07-30 2016-09-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗アクチビンａ抗体及びその使用
JP2018510637A (ja) * 2015-03-26 2018-04-19 アクセルロン ファーマ， インコーポレイテッド フォリスタチン関連融合タンパク質およびその使用

Also Published As

Publication number Publication date
AU2021377176A1 (en) 2023-06-22
KR20230118573A (ko) 2023-08-11
MX2023005565A (es) 2024-02-23
CA3197104A1 (en) 2022-05-19
WO2022103660A1 (en) 2022-05-19
EP4243931A4 (en) 2025-01-01
EP4243931A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
JP7850417B2 (ja) 新規インターロイキン－２バリアントおよびその二官能性融合分子
JP6959487B2 (ja) 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質
KR100389711B1 (ko) 사람gp39에대한인간화된항체,이들을함유하는조성물및이들의치료학적용도
JP2021528105A (ja) インターロイキン−２バリアントおよびその使用方法
CN110505883A (zh) 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
JP2022101631A (ja) 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
JP2019535675A (ja) 新規なハイブリッドａｃｔｒｉｉｂリガンドトラップタンパク質を用いた筋消耗及び骨疾患の治療方法
KR20220071264A (ko) 항-pd-l1 항원 결합 단백질 및 이의 응용
US20230391863A1 (en) Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
JP2023530433A (ja) 形質転換成長因子β（ＴＧＦβ）結合剤及びその使用
JP2023548399A (ja) Ｔｇｆ－ベータファミリーの複数のリガンドを阻害する能力を有する新規の二機能性多特異性アンタゴニストおよびその使用
RU2858732C2 (ru) Бифункциональные антагонисты активина/TGF-бета и RANKL и их применение
JP2023548346A (ja) アクチビン／ｔｇｆ－ベータおよびｒａｎｋｌの二機能性アンタゴニストならびにその使用
US20230391880A1 (en) Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
TW202417483A (zh) 結合nkg2d、cd16及ceacam5之蛋白質
RU2851121C1 (ru) Новые бифункциональные мультиспецифические антагонисты, способные ингибировать множественные лиганды семейства tgf-бета, и их применения
JP2023546759A (ja) 腫瘍壊死因子－アルファおよびトランスフォーミング増殖因子－ベータの二機能性アンタゴニストならびにその使用
CN116917330A (zh) 激活蛋白/TGF-β和RANKL的双功能拮抗剂及其用途
CN116635059A (zh) 激活蛋白和肿瘤坏死因子-α的双功能拮抗剂及其用途
CN116801895A (zh) 新颖的能够抑制TGF-β家族多于一种配体的双功能多特异性拮抗剂及其用途
JP2024533616A (ja) 新規のＷｎｔアゴニスト抗体およびその治療的使用
CN118103406A (zh) 可激活多肽复合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323